Prostatic calculi cause osteoblastic immunophenotype of prostate cancer
DOI:
https://doi.org/10.14739/2310-1237.2019.2.177099Keywords:
prostate cancer, prostatic calculi, bone neoplasms, osteotropism, osteoblastic immunophenotypeAbstract
Prostate cancer (PGC) is leading the way in the structure of cancer morbidity around the world. The presence of prostatic concretions (PC) and skeletal metastases significantly reduces the patients’ life quality and worsens the prognosis of the disease.
Aim. The aim of study was to define the impact of PC on the development of prostate cancer bone metastases.
Materials and methods. 30 samples of PGC with PC and 30 PGC tissue samples without PC were analyzed by histology (hematoxylin-eosin staining), histochemistry (von Kossa and Alizarin red staining), immunohistochemistry (OSN, Col I, Col II, p53, Bax, Casp3, MPO, CD68). PC were analyzed by SEM-EDS and XRD with different temperature of heat pretreatment.
Results. All PC samples had the calcium hydroxyapatite origin with a slight deviation from the stoichiometric composition and admixture of extraneous elements. The presence of zinc oxide and iron-containing calcium phosphate in the structure of PC was found by XRD. We revealed significantly higher expression of Вах, Саsp3, MPO and CD68 in PGC tissue with PC (P < 0.001). We suggest that the combination of these factors predetermines the development of a specific phenotype of cancer cells which is manifested by the significantly higher OSN and Col I expression in PGC with PC (P < 0.001). It contributes to recognizing of bone tissue as an optimal environment for the growth and development of PGC metastases by cancer cells.
Conclusions. The presence of PC in the PGC tissue promotes the development of a specific osteoblastic immunophenotype of cancer cells. It can determine the tropism of PGC metastases to bone tissue.
References
Chen, S. L., Wang, S. C., Ho, C. J., Kao, Y. L., Hsieh, T. Y., Chen, W. J. et al. (2017). Prostate Cancer Mortality-To Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries. Sci. Rep, 7, 40003. doi: 10.1038/srep40003
Hensel, J., & Thalmann, G. N. (2016). Biology of Bone Metastases in Prostate Cancer. Urology, 92, 6–13. doi: 10.1016/j.urology.2015.12.039
Bernstein, A. N., Shoag, J. E., Golan, R., Halpern, J. A., Schaeffer, E. M., Hsu, W. C. et al. (2018). Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases, J. Urol, 199(6), 1510–1517. doi: 10.1016/j.juro.2017.12.048
Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res, 12(20 Pt 2), 6243s–6249s. doi: 10.1158/1078-0432.CCR-06-0931
Sfanos, K. S., Isaacs, W. B., & De Marzo, A. M. (2013). Infections and inflammation in prostate cancer. Am J Clin Exp Urol, 1(1), 3–11.
Dell'Atti, L., Galosi, A.B., & Ippolito, C. (2016). Prostatic calculi detected in peripheral zone of the gland during a transrectal ultrasound biopsy can be significant predictors of prostate cancer. Arch. Ital. Urol. Androl, 88(4), 304–307. doi: 10.4081/aiua.2016.4.304.
Sfanos, K. S., Wilson, B. A., De Marzo, A. M., & Isaacs, W. B. (2009). Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc. Natl. Acad. Sci. U.S.A., 106(9), 3443–3448. doi: 10.1073/pnas.0810473106
Hagberg Thulin, M., Jennbacken, K., Damber, J. E., & Welén, K. (2014). Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin. Exp. Metastasis, 31(3), 269–283. doi: 10.1007/s10585-013-9626-1
Kawai M., & Rosen C. J. (2012). The Insulin-Like Growth Factor System in Bone. Basic and Clinical Implications. Endocrinol. Metab. Clin. North Am, 41(2), 323–333. doi: 10.1016/j.ecl.2012.04.013
Park, S. H., Eber, M. R., Widner, D. B., & Shiozawa, Y. (2018). Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases. Cancers (Basel), 10(5). doi: 10.3390/cancers10050141
Rucci, N., & Teti, A. (2010). Osteomimicry: how tumor cells try to deceive the bone. Frontiers in Bioscience, 2(3), 907–915. doi: 10.2741/S110
Gdowski, A. S., Ranjan, A., & Vishwanatha, J. K. (2017). Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J. Exp. Clin. Cancer Res, 36(1), 108. doi: 10.1186/s13046-017-0578-1
Moskalenko, R., Romanyuk, A., Danilchenko, S., Stanislavov, O., Piddubniy, A., Zakorko, I.-М., & Tkach G. (2013). Morphogenetic aspects of biomineralization on the background of benign prostatic hyperplasia. Georgian Medical News, 214, 54–61.
Dessombz, A., Méria, P., Bazin, D., & Daudon, M. (2012). Prostatic Stones: Evidence of a Specific Chemistry Related to Infection and Presence of Bacterial Imprints. PLoS One, 7(12), e51691. doi: 10.1371/journal.pone.0051691
Hyun, J. S. (2018). Clinical Significance of Prostatic Calculi: A Review. The World Journal of Men's Health, 36(1), 15–21. doi: 10.5534/wjmh.17018
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
